

#### HELPING HEALTH SYSTEMS BETTER PREPARE FOR BREAKTHROUGH MEDICINES: PROFILING AN INNOVATIVE NEW TOOL

January 17, 2025

12:00 PM EST



**MARTINE ELIAS** 

Chief Executive Officer at Myeloma Canada and Co-Chair of the Collective Oncology Network for Exchange



#### Former ADM of Alberta Drug Program and Vice Chair of pCPA



Principal, Santis Health




# Video Demonstration of the System Readiness Tool



# Focusing on the "Last Mile" of Market Access



#### What is 120? Patients Need Innovation <u>AND</u> Implementation



MYFI OM/

- The <u>development</u> of breakthrough therapies is advancing at a faster rate than ever before.
- Unfortunately, the <u>delivery</u> of those same therapies is falling farther behind – due to the increasing complexity of implementation.
- There is a huge need across Canada to connect drug plans and health system leaders to maximize the value of these therapies.

### What is 120? Improving the Implementation of Therapies

Through a country comparator jurisdictional scan, we found that although time and resources are dedicated to the approval process, **maximizing breakthrough therapies** <u>after</u> **reimbursement** is often less of a priority.



We found that there is a huge need to work collaboratively to identify – and address – the barriers and obstacles preventing health system leaders from more readily bringing new therapies to patients.



I2U's independent advisory board helps direct our efforts and validate our findings. Although Novartis provided initial funding, this work has neither a therapeutic focus nor a company one.

**U**NOVARTIS



# **Relying on Internal and External Experts**




### Our "In-House" Experts Guided by an Independent Advisory Board

The I2U Advisory Board is composed of 7 former public payers, academics, practicing clinicians, innovation experts, and patient group representatives:



**Dr. Shaan Chugh** nternal Medicine Physician, Trillium Health Partners



Martine Elias CEO, Myeloma Canada Co-Chair, ACTION



Zayna Khayat Iealth Futurist, Deloitte Canada Growth Advisor, Teladoc Health



Marcel Saulnier Former Associate ADM, Health Canada







**Graham Statt** Former ADM, Drug Plan in Alberta



Helen Stevenson Founder and CEO, Reformulary Group



**Dr. Robyn Tamblyn** Professor of Medicine, McGill University Health Centre

### Engaging with Payers and Policymakers I2U Was Also Informed by Government Interviews

I2U Advisory Board members spoke with 20+ payers and policymakers across the country. They took away some key insights:

- I2U's focus on **post-listing implementation** is important and distinctive.
- Getting health systems ready for these therapies is a **shared goal across the broader pharma policy ecosystem.**
- Part of the solution is moving beyond sequential analysis to a more integrated approach.

These insights helped I2U identify a mix of case studies that highlighted barriers to implementation <u>after</u> funding challenges have been addressed.



### Engaging with Payers and Policymakers A Wide Range of System Interviewees (I)

Organization	Title
CADTH / CDA	Vice-President, Pharmaceutical Reviews
	Vice-President, Strategic Relationships and Initiatives
	Executive Vice-President, Evidence, Products and Services
	President & CEO
рСРА	Former pCPA Chair, & ADM, Pharmaceutical, Laboratory & Blood Services
	Division, British Columbia
	pCPA Board Member, & ADM, System Overview and Strategic Services, Alberta
	pCPA Board Member, & ADM, Health Programs and Delivery, General Manager of
	OHIP, and Executive Officer of Drugs, Ontario
INESSS	President-Directrice generale
Health Canada	Director General, Pharmaceutical Drugs Directorate
	Associate Assistant Deputy Minister



#### Engaging with Payers and Policymakers A Wide Range of System Interviewees (II)

Organization	Title
ON Ministry of Health, Lab &	Director, Lab & Diagnostics Branch
Diagnostics Branch	Manager, Lab & Diagnostics Branch
	Manager, Policy Development
	Senior Program Consultant
	Senior Program Consultant
Ontario Hospital Association	President & CEO
ON Ministry of Health	Director, Ontario Public Drug Programs
Government of Alberta	Former ADM, Pharmaceutical and Supplementary Benefits Division
Alberta Heath Services	Director of Pharmacy, Cancer Services
	VP and CEO, Clinical Operations
NB Ministry of Health	Co-CEO, New Brunswick Cancer Network
BC Ministry of Health	Director, Precision Medicine and Genetic Services



# Assessing System Readiness: Building Toward a New Tool



#### Improving the Implementation of Breakthrough Therapies Developing a System Readiness Tool



PHASE 2 Case Studies & System Leader Conversations: Identifying the key system barriers delaying patient access to breakthrough therapies. PHASE 3 System Readiness Tool: Helping health system leaders, patient groups, and manufacturers identify & overcome system barriers.

The three phases outlined above have paved the way for our remarkable journey, bringing us to the exciting point we find ourselves at today.



# The Payer & Patient Perspective on System Readiness







### Our Ask of You

- 1. Please use the Tool to support your efforts to improve the implementation of breakthrough therapies.
- 2. Please share your feedback and advice so we can better understand what's working, what's not and how to make it better.

Please share your input with us – or via **info@I2U.ca** 



Access the Tool here

